Company intelligence / Profile preview

Virtue Diagnostics

Ownership: Private
Development stage: Commercial

Overview

Virtue Diagnostics develops advanced in vitro diagnostic systems for infectious disease, cancer, chronic disease, and maternal/fetal health. Its solutions span early screening through treatment monitoring. The company operates globally with a focus on emerging markets such as China and Indonesia. It recently expanded manufacturing capacity in Suzhou and Indonesia and acquired Labtest Diagnostics in Brazil to strengthen its presence in Latin America. It raised $100 million Series B funding in September 2023.

Therapeutic areas: Women's HealthOncologyEndocrinologyInfectious Diseases
Modalities: Clinical mass spectrometry (Clinical MS)Multiplex immunohistochemistryMolecular assay platformsImmunoassay platformsDevice (diagnostic instruments)Reagent manufacturing
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Virtue Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virtue Diagnostics.

Explore the full profile